This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): sepantronium bromide
Description: YM155 is a small molecule in injectable form that is expected to induce programmed cell death (apoptosis) in tumor tissue by suppressing survivin, an inhibitor of apoptosis.
Deal Structure: In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.
Pink Sheet Weekly Trademark Review May 12, 2015
Additional information available to subscribers only: